Expanded Access to Everolimus, for an Individual Patient NCT03493165

Updated 06/21/2024

Clinical Trial Details — Status: Available

Administrative data
NCT number	NCT03493165
Other study ID #	CTMS# 18-0020
Secondary ID
Status	Available
Phase
First received
Last updated

Study information
Verified date	November 2023
Source	The University of Texas Health Science Center at San Antonio
Contact	John Sarantopoulos, MD
Phone	210-450-1785
Email	sarantopoulo[@]uthscsa.edu
Is FDA regulated	No
Health authority
Study type	Expanded Access

Clinical Trial Summary

Single patient treatment with everolimus.

Recruitment information / eligibility
Status	Available
Enrollment	0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender	Female
Age group	18 Years and older
Eligibility

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Everolimus
mTOR inhibitor

Locations
Country	Name	City	State
n/a

Sponsors *(1)*
Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02096783` - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer	N/A
	Recruiting	`NCT00162721` - The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas	Phase 3
	Completed	`NCT01806350` - Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors	N/A
	Recruiting	`NCT05881967` - Molecular Mechanism Study of Uterine Sarcoma
	Active, not recruiting	`NCT06244251` - Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids	N/A
	Completed	`NCT00020267` - Vaccine Therapy in Treating Patients With Metastatic Cancer	Phase 1
	Recruiting	`NCT04224467` - The Application of Real-Time Near-infrared Imaging in Gynecological Surgery	N/A
	Active, not recruiting	`NCT01979393` - IRCI Gynae Sarcomas, High Grade Uterine Sarcoma	Phase 2
	Completed	`NCT01303094` - Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma	Phase 2